PMC:7546122 / 4122-4692
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T17 | 60-66 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
| T18 | 168-174 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
| T19 | 241-246 | Body_part | denotes | blood | http://purl.org/sig/ont/fma/fma9670 |
| T20 | 423-425 | Body_part | denotes | AG | http://purl.org/sig/ont/fma/fma61898 |
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T1 | 241-246 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/UBERON_0000178 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T23 | 105-113 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T35 | 18-19 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
| T36 | 60-66 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
| T37 | 168-174 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
| T38 | 241-246 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
| T39 | 241-246 | http://www.ebi.ac.uk/efo/EFO_0000296 | denotes | blood |
| T40 | 460-466 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tested |
| T41 | 528-529 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T24 | 0-17 | Sentence | denotes | IVIG Preparations |
| T25 | 18-130 | Sentence | denotes | A total of 54 IVIG lots fractionated from plasma collected prior to the circulation of SARS-CoV-2 were analyzed. |
| T26 | 131-435 | Sentence | denotes | The IVIG lots were manufactured from plasma either donated by plasmapheresis (source) or recovered from whole-blood donations (recovered), in the United States (Gammagard Liquid; Baxter Healthcare Corp.; n = 30) or central Europe, that is Austria, Germany, and Czech Republic (KIOVIG; Baxter AG; n = 24). |
| T27 | 436-570 | Sentence | denotes | These 54 IVIG lots were tested in 2 independent experiments for nAbs (1 European lot was in a single assay due to volume constraints). |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 98 | 105-115 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 99 | 500-504 | Chemical | denotes | nAbs |